cdc.gov/coronavirus
When You’ve Been Fully Vaccinated:
Interim Public Health Recommendations
1
Dr. Cynthia Ogden, Science Officer in support of the
Chief Medical Officer, CDC COVID-19 Emergency Response
Tami Hilger Skoff, Epidemiologist on the Clinical
Guidelines Team, Vaccine Task Force, CDC COVID-19
Emergency Response
(Moderator) Nora Spencer-Loveall, Deputy for Partnerships
and Risk Management, CDC COVID-19 Emergency
Response
Enter your email and then search for
“COVID-19 (Coronavirus) Partners”
Agenda
 Introduction
 Science Update
 Overview of Interim Recommendations for
Fully Vaccinated Persons
 Q&A from emails received​
 Closing​
Subscribe to get future call announcements:
https://tools.cdc.gov/campaignproxyservice/subscriptions.asp
x
2
This call will be recorded and archived
on cdc.gov and on YouTube.
Search: "cdc partner call"
or "cdc youtube partner call“
Q&A: We collect, sort and prep for
questions prior to the call so we can
answer as many as possible
Notes
CDC.gov Resources
3
Today's Panelists
Dr. Cynthia Ogden
Science Officer in support of the Chief Medical Officer
CDC COVID-19 Emergency Response
Tami Hilger Skoff
Epidemiologist, Clinical Guidelines Team, Vaccine Task Force
CDC COVID-19 Emergency Response
4
cdc.gov/coronavirus
Updates on COVID-19
Dr. Cynthia Ogden
Science Officer in support of the
Chief Medical Officer
CDC COVID-19 Emergency Response
5
COVID-19 Situational Update
 Global
• Cumulative Deaths: 2,709,041
 United States
• Cumulative Deaths: 539,038
• Average deaths last 7 days: 1032/day
• Average previous 7 days: 1,247/day
• -20.8% decrease over previous 7 days
 Global
• Cumulative Cases: 122,822,505
 United States
• Cumulative Cases: 29,613,017
• Average cases last 7 days: 54,369/day
• Average previous 7 days: 53,546/day
• 1.5% increase over previous 7 days
6
This information is current as of March 20, 2021.
Source for U.S. information: https://covid.cdc.gov/covid-data-tracker/#datatracker-home
Source for global information: https://covid19.who.int/table
COVID-19 Science Update
7
March 12: Morbidity and Mortality Weekly Report – "Body Mass Index and Risk for COVID-19–Related
Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death — United States,
March–December 2020“
• https://www.cdc.gov/mmwr/volumes/70/wr/mm7010e4.htm?s_cid=mm7010e4_w
March 19: Morbidity and Mortality Weekly Report – "Association of Children’s Mode of School
Instruction with Child and Parent Experiences and Well-Being During the COVID-19 Pandemic — COVID
Experiences Survey, United States, October 8–November 13, 2020"
• https://www.cdc.gov/mmwr/volumes/70/wr/mm7011a1.htm?s_cid=mm7011a1_w
March 19: Morbidity and Mortality Weekly Report – “Racial and Ethnic Disparities in COVID-19
Incidence by Age, Sex, and Period Among Persons Aged <25 Years — 16 U.S. Jurisdictions, January 1–
December 31, 2020”
• https://www.cdc.gov/mmwr/volumes/70/wr/mm7011e1.htm?s_cid=mm7011e1_x
cdc.gov/coronavirus
Interim Recommendations for Fully Vaccinated Persons
Tami Hilger Skoff
Epidemiologist, Clinical Guidelines Team
Vaccine Task Force
CDC’s COVID-19 Emergency Response
8
When you have been Fully Vaccinated:
Interim Public Health Recommendations
9
COVID-19 vaccinations in the United States
 As of March 21, 2021
– Total Vaccine Doses Administered
• 124,481,412
– People Vaccinated
• At lease one dose: 24.5%
• Fully vaccinated: 13.3%
Available: https://covid.cdc.gov/covid-data-tracker
Fully vaccinated* people can:
 Visit with other fully vaccinated people indoors, no masks or distancing
 Visit with other unvaccinated people from a single household, if low risk,
indoors, no masks, no distancing
 Refrain from quarantine and testing following a known exposure to COVID-
19 if asymptomatic
* ≥2 weeks after the second dose in a 2-dose series (Pfizer-BioNTech or Moderna), or ≥2 weeks after a single-dose vaccine (Johnson and
Johnson [J&J]/Janssen)
Visits between fully vaccinated people
& unvaccinated people
 Recommendation for prevention measures depends on:
– Underlying risks for severe COVID-19 among unvaccinated people and
members of their households
– Number of households with unvaccinated persons
No Prevention Measures Needed
• Unvaccinated people are from a single
household & are at low risk of severe
COVID-19
Prevention Measures Needed
• Unvaccinated people are from a single
household & at high risk for severe COVID-19
• Unvaccinated people are from multiple
households
For now, fully vaccinated people should continue to:
 Take precautions in public, mask and distancing
 Avoid medium- and large-sized in-person gatherings
 Get tested if experiencing COVID-19 symptoms
 Follow guidance issued by individual employers
 Follow CDC and health department travel requirements and
recommendations
Supporting scientific evidence
 Fully vaccinated people are at low risk of symptomatic & severe COVID-19
 Fully vaccinated people are less likely to have asymptomatic infection and
potentially less likely to transmit SARS-CoV-2 to others
 COVID-19 vaccines will likely be effective against a variety of emerging
variants, however continued monitoring of emerging variants is critical
– Reduced neutralizing antibody activity and efficacy observed for B.1.351
variant
 Further information on evidence and considerations related to these
recommendations is available in the new Science Brief
Web links
 Interim Public Health Recommendations for Fully Vaccinated People
– https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated-
guidance.html
 Science Brief: Background Rationale and Evidence for Public Health
Recommendations for Fully Vaccinated People
– https://www.cdc.gov/coronavirus/2019-ncov/more/fully-vaccinated-
people.html
 When You’ve Been Fully Vaccinated: How to Protect Yourself and Others
– https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated.html
Q&A with Panelists
Notes
This call will be recorded and archived on
cdc.gov and on YouTube.
Search: "cdc partner call" or "cdc
youtube partner call“
Make sure to send questions in
by 3/25 for the next call.
Dr. Cynthia Ogden
Science Officer in support of the Chief Medical Officer,
CDC COVID-19 Emergency Response
Tami Hilger Skoff
Epidemiologist, Clinical Guidelines Team
Vaccine Task Force
16
Next Call (3/29): “Understanding the Impact of Telehealth Usage During the COVID-
19 Pandemic"
Closing
Subscribe to get future call announcements: https://tools.cdc.gov/campaignproxyservice/subscriptions.aspx
Enter your email and then search for "COVID-19 (Coronavirus) Partners"
This call will be posted on cdc.gov and CDC's YouTube channel.
Search "cdc partner call" or "cdc youtube partner call"
For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the
official position of the Centers for Disease Control and Prevention.
17

2020.03.22-PartnerUpdateSlides.pptx

  • 1.
    cdc.gov/coronavirus When You’ve BeenFully Vaccinated: Interim Public Health Recommendations 1 Dr. Cynthia Ogden, Science Officer in support of the Chief Medical Officer, CDC COVID-19 Emergency Response Tami Hilger Skoff, Epidemiologist on the Clinical Guidelines Team, Vaccine Task Force, CDC COVID-19 Emergency Response (Moderator) Nora Spencer-Loveall, Deputy for Partnerships and Risk Management, CDC COVID-19 Emergency Response
  • 2.
    Enter your emailand then search for “COVID-19 (Coronavirus) Partners” Agenda  Introduction  Science Update  Overview of Interim Recommendations for Fully Vaccinated Persons  Q&A from emails received​  Closing​ Subscribe to get future call announcements: https://tools.cdc.gov/campaignproxyservice/subscriptions.asp x 2 This call will be recorded and archived on cdc.gov and on YouTube. Search: "cdc partner call" or "cdc youtube partner call“ Q&A: We collect, sort and prep for questions prior to the call so we can answer as many as possible Notes
  • 3.
  • 4.
    Today's Panelists Dr. CynthiaOgden Science Officer in support of the Chief Medical Officer CDC COVID-19 Emergency Response Tami Hilger Skoff Epidemiologist, Clinical Guidelines Team, Vaccine Task Force CDC COVID-19 Emergency Response 4
  • 5.
    cdc.gov/coronavirus Updates on COVID-19 Dr.Cynthia Ogden Science Officer in support of the Chief Medical Officer CDC COVID-19 Emergency Response 5
  • 6.
    COVID-19 Situational Update Global • Cumulative Deaths: 2,709,041  United States • Cumulative Deaths: 539,038 • Average deaths last 7 days: 1032/day • Average previous 7 days: 1,247/day • -20.8% decrease over previous 7 days  Global • Cumulative Cases: 122,822,505  United States • Cumulative Cases: 29,613,017 • Average cases last 7 days: 54,369/day • Average previous 7 days: 53,546/day • 1.5% increase over previous 7 days 6 This information is current as of March 20, 2021. Source for U.S. information: https://covid.cdc.gov/covid-data-tracker/#datatracker-home Source for global information: https://covid19.who.int/table
  • 7.
    COVID-19 Science Update 7 March12: Morbidity and Mortality Weekly Report – "Body Mass Index and Risk for COVID-19–Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death — United States, March–December 2020“ • https://www.cdc.gov/mmwr/volumes/70/wr/mm7010e4.htm?s_cid=mm7010e4_w March 19: Morbidity and Mortality Weekly Report – "Association of Children’s Mode of School Instruction with Child and Parent Experiences and Well-Being During the COVID-19 Pandemic — COVID Experiences Survey, United States, October 8–November 13, 2020" • https://www.cdc.gov/mmwr/volumes/70/wr/mm7011a1.htm?s_cid=mm7011a1_w March 19: Morbidity and Mortality Weekly Report – “Racial and Ethnic Disparities in COVID-19 Incidence by Age, Sex, and Period Among Persons Aged <25 Years — 16 U.S. Jurisdictions, January 1– December 31, 2020” • https://www.cdc.gov/mmwr/volumes/70/wr/mm7011e1.htm?s_cid=mm7011e1_x
  • 8.
    cdc.gov/coronavirus Interim Recommendations forFully Vaccinated Persons Tami Hilger Skoff Epidemiologist, Clinical Guidelines Team Vaccine Task Force CDC’s COVID-19 Emergency Response 8
  • 9.
    When you havebeen Fully Vaccinated: Interim Public Health Recommendations 9
  • 10.
    COVID-19 vaccinations inthe United States  As of March 21, 2021 – Total Vaccine Doses Administered • 124,481,412 – People Vaccinated • At lease one dose: 24.5% • Fully vaccinated: 13.3% Available: https://covid.cdc.gov/covid-data-tracker
  • 11.
    Fully vaccinated* peoplecan:  Visit with other fully vaccinated people indoors, no masks or distancing  Visit with other unvaccinated people from a single household, if low risk, indoors, no masks, no distancing  Refrain from quarantine and testing following a known exposure to COVID- 19 if asymptomatic * ≥2 weeks after the second dose in a 2-dose series (Pfizer-BioNTech or Moderna), or ≥2 weeks after a single-dose vaccine (Johnson and Johnson [J&J]/Janssen)
  • 12.
    Visits between fullyvaccinated people & unvaccinated people  Recommendation for prevention measures depends on: – Underlying risks for severe COVID-19 among unvaccinated people and members of their households – Number of households with unvaccinated persons No Prevention Measures Needed • Unvaccinated people are from a single household & are at low risk of severe COVID-19 Prevention Measures Needed • Unvaccinated people are from a single household & at high risk for severe COVID-19 • Unvaccinated people are from multiple households
  • 13.
    For now, fullyvaccinated people should continue to:  Take precautions in public, mask and distancing  Avoid medium- and large-sized in-person gatherings  Get tested if experiencing COVID-19 symptoms  Follow guidance issued by individual employers  Follow CDC and health department travel requirements and recommendations
  • 14.
    Supporting scientific evidence Fully vaccinated people are at low risk of symptomatic & severe COVID-19  Fully vaccinated people are less likely to have asymptomatic infection and potentially less likely to transmit SARS-CoV-2 to others  COVID-19 vaccines will likely be effective against a variety of emerging variants, however continued monitoring of emerging variants is critical – Reduced neutralizing antibody activity and efficacy observed for B.1.351 variant  Further information on evidence and considerations related to these recommendations is available in the new Science Brief
  • 15.
    Web links  InterimPublic Health Recommendations for Fully Vaccinated People – https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated- guidance.html  Science Brief: Background Rationale and Evidence for Public Health Recommendations for Fully Vaccinated People – https://www.cdc.gov/coronavirus/2019-ncov/more/fully-vaccinated- people.html  When You’ve Been Fully Vaccinated: How to Protect Yourself and Others – https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated.html
  • 16.
    Q&A with Panelists Notes Thiscall will be recorded and archived on cdc.gov and on YouTube. Search: "cdc partner call" or "cdc youtube partner call“ Make sure to send questions in by 3/25 for the next call. Dr. Cynthia Ogden Science Officer in support of the Chief Medical Officer, CDC COVID-19 Emergency Response Tami Hilger Skoff Epidemiologist, Clinical Guidelines Team Vaccine Task Force 16 Next Call (3/29): “Understanding the Impact of Telehealth Usage During the COVID- 19 Pandemic"
  • 17.
    Closing Subscribe to getfuture call announcements: https://tools.cdc.gov/campaignproxyservice/subscriptions.aspx Enter your email and then search for "COVID-19 (Coronavirus) Partners" This call will be posted on cdc.gov and CDC's YouTube channel. Search "cdc partner call" or "cdc youtube partner call" For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. 17